Switch theme
Sign up to access all valuation multiples
Ajanta Pharma Ltd is a drug manufacturing company with a focus on specialty pharmaceutical products. The company maintains a presence while generating the vast majority of its revenue in India. The company aims to successfully select molecules and products for development while enhancing its research and development capabilities. The company works to develop formulations in different dosages such as tablets, creams, injectables, capsules, liquids, and lotion. The company's manufacturing plants are located in India.
1979
9.6K+
LTM Revenue $560M
LTM EBITDA $153M
$3.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ajanta Pharma has a last 12-month revenue (LTM) of $560M and a last 12-month EBITDA of $153M.
In the most recent fiscal year, Ajanta Pharma achieved revenue of $535M and an EBITDA of $158M.
Ajanta Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ajanta Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $560M | XXX | $535M | XXX | XXX | XXX |
| Gross Profit | $431M | XXX | $404M | XXX | XXX | XXX |
| Gross Margin | 77% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $153M | XXX | $158M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 30% | XXX | XXX | XXX |
| EBIT | $137M | XXX | $132M | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $111M | XXX | $107M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Ajanta Pharma's stock price is INR 2506 (or $29).
Ajanta Pharma has current market cap of INR 313B (or $3.7B), and EV of INR 307B (or $3.6B).
See Ajanta Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.6B | $3.7B | XXX | XXX | XXX | XXX | $0.89 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Ajanta Pharma has market cap of $3.7B and EV of $3.6B.
Ajanta Pharma's trades at 6.9x EV/Revenue multiple, and 23.1x EV/EBITDA.
Equity research analysts estimate Ajanta Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ajanta Pharma has a P/E ratio of 32.9x.
See valuation multiples for Ajanta Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.7B | XXX | $3.7B | XXX | XXX | XXX |
| EV (current) | $3.6B | XXX | $3.6B | XXX | XXX | XXX |
| EV/Revenue | 6.4x | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBITDA | 23.4x | XXX | 23.1x | XXX | XXX | XXX |
| EV/EBIT | 26.2x | XXX | 27.7x | XXX | XXX | XXX |
| EV/Gross Profit | 8.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 32.9x | XXX | 35.0x | XXX | XXX | XXX |
| EV/FCF | 41.3x | XXX | 39.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAjanta Pharma's last 12 month revenue growth is 13%
Ajanta Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $28K for the same period.
Ajanta Pharma's rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ajanta Pharma's rule of X is 59% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ajanta Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 42% | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $28K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ajanta Pharma acquired XXX companies to date.
Last acquisition by Ajanta Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Ajanta Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ajanta Pharma founded? | Ajanta Pharma was founded in 1979. |
| Where is Ajanta Pharma headquartered? | Ajanta Pharma is headquartered in India. |
| How many employees does Ajanta Pharma have? | As of today, Ajanta Pharma has 9.6K+ employees. |
| Is Ajanta Pharma publicy listed? | Yes, Ajanta Pharma is a public company listed on BOM. |
| What is the stock symbol of Ajanta Pharma? | Ajanta Pharma trades under 532331 ticker. |
| When did Ajanta Pharma go public? | Ajanta Pharma went public in 2000. |
| Who are competitors of Ajanta Pharma? | Similar companies to Ajanta Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ajanta Pharma? | Ajanta Pharma's current market cap is $3.7B |
| What is the current revenue of Ajanta Pharma? | Ajanta Pharma's last 12 months revenue is $560M. |
| What is the current revenue growth of Ajanta Pharma? | Ajanta Pharma revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Ajanta Pharma? | Current revenue multiple of Ajanta Pharma is 6.4x. |
| Is Ajanta Pharma profitable? | Yes, Ajanta Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ajanta Pharma? | Ajanta Pharma's last 12 months EBITDA is $153M. |
| What is Ajanta Pharma's EBITDA margin? | Ajanta Pharma's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Ajanta Pharma? | Current EBITDA multiple of Ajanta Pharma is 23.4x. |
| What is the current FCF of Ajanta Pharma? | Ajanta Pharma's last 12 months FCF is $86.8M. |
| What is Ajanta Pharma's FCF margin? | Ajanta Pharma's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Ajanta Pharma? | Current FCF multiple of Ajanta Pharma is 41.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
